Navigation Links
Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting

Data on six products from Pharmion's pipeline provide support for epigenetic and combination therapies, including promising Phase III data on use of Thalidomide to treat multiple myeloma

BOULDER, Colo., May 31, 2007 /PRNewswire-FirstCall/ -- Pharmion Corporation reported today that data from 18 abstracts of studies investigating the company's marketed and pipeline products will be presented or published at the American Society of Clinical Oncology's (ASCO) 43rd Annual Meeting in Chicago (June 1-5, 2007). These abstracts include summaries of data from studies of each of the six key products in the company's commercial and development portfolio, for multiple indications, including Myelodysplastic Syndromes (MDS), multiple myeloma, Hodgkin's lymphoma, small cell lung cancer and advanced hormone-refractory prostate cancer.

"ASCO 2007 provides further evidence of Pharmion's progress," said Patrick J. Mahaffy, president and chief executive officer of Pharmion. "Data from six of our products will be presented or published, including Phase III data for Satraplatin and Thalidomide, encouraging Phase II data for Amrubicin, Vidaza and MGCD0103, and human bioavailability data for oral azacitidine. These data demonstrate the strength of the Pharmion business model; we are focused solely on oncology, we have multiple compounds demonstrating clinical benefit, and we have a U.S. and international infrastructure to support those products. Pharmion is well-positioned to take full advantage of the strong portfolio of products in our pipeline."

"The data at ASCO affirm Pharmion's leadership in developing epigenetic therapies as a promising approach to treating cancer," said Andrew R. Allen, Pharmion's chief medical officer. "MGCD0103, our class-selective HDAC inhibitor, is showing meaningful activity as monotherapy in advanced Hodgkin's lymphoma. Furthermore, as we begin to understand the way in which multiple epigen
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference

Post Your Comments:
(Date:11/25/2009)...CITY,Calif.,Nov.25/PRNewswire-FirstCall/--Abaxis,I...uringpoint-of-carebloodanalysissystems,announcedto...cer,willpresentatthe21stAnnualPiperJaffrayHealthCa....TheconferencewillbeheldattheNewYorkPalaceHotelinN...ps,manufacturesandmarketsportablebloodanalysissyst...
(Date:11/25/2009)...RK,Nov.25/PRNewswire/--Reportlinker.comannouncesth...e: ,, PainManagement-GlobalTrends ,, ht...---Global-Trends.html ,, Widespreadavailabilit...ndtheadventofnewdrugshaveacceleratedthepaceofgrowt...mbursementstructurecontinuetoshapedemandforservice...
(Date:11/24/2009)...SDA,Md.,Nov.24/PRNewswire-Asia/--ChindexInternatio...ndentAmericanproviderofWestern,healthcareproductsa...ncedthattheCompanywillattendthe21stAnnualPiperJaff...er1-2,2009,atthe,NewYorkPalaceHotel. , Manage...day,December1,2009,andholdone-on-onemeetingsthrou...
Breaking Medicine Technology:Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Chindex International to Present at Piper Jaffray Health Care Conference 2Model for new generation of blood vessels challenged 47467 1Model for new generation of blood vessels challenged 47467 2New study finds lowfat chocolate milk is effective post exercise recovery aid for soccer players 8670 1New study finds lowfat chocolate milk is effective post exercise recovery aid for soccer players 8670 2New Compact and Folding Reading Glasses from VisAcuity com 3A Never Leave Home Without Them 47465 1New Compact and Folding Reading Glasses from VisAcuity com 3A Never Leave Home Without Them 47465 2
...mmune marker in healthy people , , CLEVELAND, May...ate Medicine suggests that a specific strain of ..., increases the body,s immune response to the flu ... in T-cell production of TNF-alpha, a key immune m... in healthy adults who consumed a daily capsule of...
...Rx Pharmaceuticals, Inc. today announced that it h...1 Sufentanil NanoTab(TM) PCA System, a proprietary...eveloped for management of acute post-operative pa... of this open-label study is to assess the functio...n management in patients undergoing unilateral kne...
Other Medicine Technology:New Study Shows Probiotic Strain Effective in Boosting Immune Response to Flu Virus 2New Study Shows Probiotic Strain Effective in Boosting Immune Response to Flu Virus 3New Study Shows Probiotic Strain Effective in Boosting Immune Response to Flu Virus 4New Study Shows Probiotic Strain Effective in Boosting Immune Response to Flu Virus 5AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System 2AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System 3
(Date:11/26/2009)...ntal (RTDental), a leading dental group practice i...nsion of its services to include LUMINEERS by a ce..., Durham, NC (PRWEB) -- Re... Dr. Doug Macmillan, an experienced LUMINEERS De...raining seminar. RTDental’s ability to fulf...
(Date:11/25/2009)...re/--WhenmostpeopleheartheacronymTMJ,theythinkofth...elptheyneed.TMJstandsfortheTemporal-MandibularJoin...thyourskull(temporalbone). ,, Themostcommonsymp...,clickingorpoppingofthejaw.Butmanyothersymptomscan...gue,sleepdisturbances,irritability,alossinfocus,ri...
(Date:11/25/2009)...entinelleMedicalInc.,aleadingmanufacturerofMagneti...ientificInc.,aleadingproviderofsoftwareenablingtec...st4DAdvancedVisualizationsoftware. ,, Thisinnov...ntbasedmedicalimagingofferinginthemarket.CalgarySc...ntaccess-requiringnosoftwaredownload,andrunsonanyM...
(Date:11/25/2009)...ewswire/--AnarticlebyJanetWoodcock,M.D.,directorof...ADifficultBalance-PainManagement,DrugSafety,andthe...urnalofMedicine. ,, (Logo: http://www.newscom.c...cle,WoodcockdiscussesFDAeffortstostrikeabalancebet...gingtherisksposedbyvariousanalgesics.Asexamples,sh...
(Date:11/25/2009)...ndPressJoinEfforttoEducate ,, MEMPHIS,Tenn.,No...BipolarFoundationandtheMedicAlertFoundationreceive...,whichisnowbeingwidelyacceptedasapreventivehealthc...larFoundationreceivedaproclamationofendorsementvia...sianaMitchLandrieu.TheNationalBipolarFoundationsta...
Breaking Medicine News(10 mins):Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3
...ments may further increase the risk of breast and ...ose diseases. //Researchers offer new evidence tha...ionally used for gynecological complaints - as wel...le all the plants can successfully be used to ease...
...ould more than double their daily exercise time in...advised to aim for 35 minutes a day// of moderate ...ists at the University of Alabama at Birmingham no...ed for 60 per cent of the weight gain - with food ...
... Hyperactivity Disorder - ADHD - have underactive ..., thinking and planning. The abnormality was revea...researchers to look at the brains of children with...nghtened claims that the controversial disease has...
...he harm unhealthy habits do can motivate them to c...of studies on biomarkers indicators of health or ...n affect people's behaviour. They learned th...emselves. Other factors that are useful to know ar...
...ins the progress of a catastrophic conditions in o...62% of patients who undergo heart transplants deve...osclerosis, in the first three years after their s...study. Dr James Fang, who led the research, called...
...during pregnancy can increase a mother's risk of h...women who were very anxious// in the last three mo...al problems. Lead researcher Professor Vivet... a survey antenatal anxiety leads to the risk of h...
Other Medicine News:
...powder reagent once reconstituted offers the labor...ty to help maximize laboratory productivity, minim...ound time. The proprietary technology of the Infin...helf life and stability once reconstituted that wi...
...nase powder reagent once reconstituted offers the ...ability to help maximize laboratory productivity, ...urnaround time. The proprietary technology of the ...s a long shelf life and stability once reconstitut...
Infinity™ Ammonia
Velo® 300M Wavefront Lens Analyzer
Medicine Products: